Dong Hwan Kim, M.D.,Ph.D. [clinicaltrials_resource:983425237b2ec285001f3371b8532a9d]
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia [clinicaltrials:NCT01039363]Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia [clinicaltrials:NCT01066286]Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype [clinicaltrials:NCT01066338]Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia [clinicaltrials:NCT01079507]
overall contact [clinicaltrials_vocabulary:overall-contact]
Dong Hwan Kim, M.D.,Ph.D. [clinicaltrials_resource:983425237b2ec285001f3371b8532a9d]
Bio2RDF identifier
983425237b2ec285001f3371b8532a9d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:983425237b2ec285001f3371b8532a9d
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
dr.dennis.kim@samsung.com
last name [clinicaltrials_vocabulary:last-name]
Dong Hwan Kim, M.D.,Ph.D.
phone [clinicaltrials_vocabulary:phone]
+82-2-3410-1768
role [clinicaltrials_vocabulary:role]
Principal Investigator
identifier
clinicaltrials_resource:983425237b2ec285001f3371b8532a9d
title
Dong Hwan Kim, M.D.,Ph.D.
@en
type
label
Dong Hwan Kim, M.D.,Ph.D. [clinicaltrials_resource:983425237b2ec285001f3371b8532a9d]
@en